/Charles%20River%20Laboratories%20International%20Inc_%20chart%20and%20logo-by%20IgorGolovniov%20via%20Shutterstock.jpg)
With a market cap of $8.1 billion, Charles River Laboratories International, Inc. (CRL) is a leading full-service, early-stage contract research organization. The company supports global pharmaceutical, biotechnology, government, and academic clients with research models, drug discovery, safety assessment, and manufacturing solutions to accelerate drug development.
Shares of the Wilmington, Massachusetts-based company have underperformed the broader market over the past 52 weeks. CRL stock has dipped nearly 20% over this time frame, while the broader S&P 500 Index ($SPX) has gained 15.1%. Moreover, shares of the company have decreased 11.3% on a YTD basis, compared to SPX's 9.9% rise.
